Prevalence of inhibitors and clinical characteristics in patients with haemophilia in a middle‐income Latin American country

Prevalence of inhibitors and clinical characteristics in patients with haemophilia in a middle‐income Latin American country

Introduction Development of inhibitors is the most serious complication in patients with haemophilia (PWH). The prevalence of inhibitors in patients with severe haemophilia A (HA) is approximately 25%‐30%. Inhibitor prevalence differs among populations. Some studies report a prevalence of almost twi...

Full description

Saved in:
Bibliographic Details
Published in:Haemophilia : the official journal of the World Federation of Hemophilia Vol. 26; no. 2; pp. 290 - 297
Main Authors: Villarreal‐Martínez, Laura, García‐Chávez, Jaime, Sánchez‐Jara, Berenice, Moreno‐González, Aida Mashenka, Soto‐Padilla, Janet, Aquino‐Fernández, Efraín, Paredes‐Aguilera, Rogelio, Maldonado‐Silva, Karla, Rodríguez‐Castillejos, Cecilia, González‐Ávila, Ana Itamar, Mora‐Torres, María, Tiznado‐García, Hector Manuel, Padilla‐Durón, Natalia Elizabeth, Luna‐Silva, Nuria Citlali, Gutiérrez‐Juárez, Eric Israel, Nemi‐Cueto, Jorge, Gómez‐González, Claudia Sofia, De León‐Figueroa, Ricardo, López‐Miranda, Adela, Ríos‐Osuna, Mirna Guadalupe, Tamez‐Gómez, Edna Liliana, Reyes‐Espinoza, Elio Aarón, Domínguez‐Varela, Irving Armando, González‐Martínez, Gerardo, Godoy‐Salinas, Elias Adán
Format: Journal Article
Language:English
Published: England Wiley Subscription Services, Inc 01-03-2020
Subjects:
haemophilia
Hemophilia
hispanic
inhibitors
Latin America
Patients
Population studies
prevalence
Risk factors
Statistical analysis
Mexico
haemophilia
hispanic
inhibitors
prevalence
Latin America
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction Development of inhibitors is the most serious complication in patients with haemophilia (PWH). The prevalence of inhibitors in patients with severe haemophilia A (HA) is approximately 25%‐30%. Inhibitor prevalence differs among populations. Some studies report a prevalence of almost twice in Hispanic as compared to Caucasian patients. Most data available, on the prevalence of inhibitors and their predisposing factors, originate from centres in developed countries. Aim Establish the prevalence of inhibitors of FVIII and FIX in Mexico. Methods This was an observational, cross‐sectional and descriptive study. The records of all patients diagnosed with haemophilia A (HA) or B (HB), with and without inhibitors, were included. Clinical and demographical characteristics of patients with inhibitors were assessed. Statistical analysis was performed using IBM SPSS version 22. The Ethics Committees of the various participating institutions approved this study. Results A total of 1455 patients from the 20 participating centres were recruited, from which 1208 (83.02%) had HA and 247 (16.97%) were diagnosed with HB. The presence of inhibitors in severe HA was reported in 93/777(11.96%), and 10/162 (6.17%) in severe HB. Of them, 91.7% exhibited high titres in HA and 100% in HB. Conclusion In Mexico, the general prevalence of inhibitors varies considerably among centres. This study established a basis of comparison for future development and advances in the treatment and follow‐up of patients. These findings also augment our understanding of risk factors related to inhibitor development.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1351-8216
1365-2516
DOI:10.1111/hae.13951